A real world study on the treatment of prostate cancer by integrated Chinese and Western medicine

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200006847

Enrollment

Unknown

Registered

2022-12-01

Start date

2022-12-05

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Prostate cancer integrated therapies group (Endocrinotherapy+Fuzheng Yiliu formulation) :None

Eligibility

Sex/Gender

Male

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1)Prostate cancer diagnosed by pathology, aged 18-90 years old; (2)Advanced or metastatic diseases,with the treatment of endocrine therapy; (3)With complete clinical data such as PSA and imaging examination data, which can evaluate drug resistance and bone metastasis; (4) With survival data or follow-up information such as telephone,etc.

Exclusion criteria

Exclusion criteria: Prostate cancer patients with early stage tumors preferred for surgery or radiotherapy.

Design outcomes

Primary

Measure	Time frame
Time to CRPC;	—

Secondary

Measure	Time frame
Overall survival;Radiographic progression-free survival;	—

Countries

China

Contacts

Public ContactJianfu Zhou

Guangdong Provincial Hosptial of Chinese Medicine

zhoujianfu@gzucm.edu.cn+86 15915728725

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026